Pharmaceutical Executive-12-01-2013

Pharmaceutical Executive
Column

February 18, 2014

A global life-cycle management strategy should be baked into a drug's initial price at launch, write Alice Swearingen and Patrick Homer.

For Patrick Lindsay, providing decision support across the full product life cycle is no stretch goal-it's today's fact of life

Pharmaceutical Executive

A patient-centric approach to drug development delivers the benefits that actually create value, writes Charlotte Vansgaard and Mikkel Brok-Kristensen.

Pharmaceutical Executive
Column

December 01, 2013

The Agency struggles to ensure access to needed medicines while minimizing potential risks, writes Jill Wechsler.

Pharmaceutical Executive

Why do some doctors prescribe more generic drugs than others?

Pharmaceutical Executive

For senior executives, meeting the requirements of a Consent Decree to the satisfaction of regulators is only half of the job.

Pharmaceutical Executive

Big Pharma and biotech continue to need each other. But biotech is feeling slightly more confident as the options for IPOs get better, writes Peter Young.

Pharmaceutical Executive
Country Report

December 01, 2013

"Science powers commerce," Canadian Prime Minister Stephen Harper remarked in 2010. In those three words, the Prime Minister summarizes a massive effort by various stakeholders to create a "brain gain" in Canada to strengthen its positioning in the world of research and technology. Despite declining investments by big pharma in recent years, the country has created a number of innovative ways to incentivize R&D and leverage its geographic reach in the North American Market.

Pharmaceutical Executive
From the Editor

December 01, 2013

New and emerging technologies are noteworthy not simply for the excellent science behind them but also for the way they expose those raw edges of the industry's business model.